Patel et al. encapsulated miR-155 in extracellular vesicles from gemcitabine-resistant pancreatic cancer cells to reduce deoxycytidine kinase (gemcitabine-metabolizing gene) and increase superoxide dismutase 2 and catalase (ROS-detoxifying genes) expression in the presence of chemotherapy [75]. Here, DCK is linked to pancreatic neoplasm.